Under the terms of the agreement, BioLineRx will grant CTTQ exclusive rights to develop, manufacture and commercialize BL-8030 in China and Hong Kong.
http://eon.businesswire.com/news/eon/20130610005556/en/BioLineRx-Enters-Collaboration-Develop-Commercialize-Hepatitis-Drug
http://eon.businesswire.com/news/eon/20130610005556/en/BioLineRx-Enters-Collaboration-Develop-Commercialize-Hepatitis-Drug
No comments:
Post a Comment